Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.70 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.65 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
| ▸ | PARG | Q86W56 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419143 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL29476737 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL19493160 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL29476738 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL250252 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL23982340 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL12932304 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL250251 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL23856115 | 0.99 | P2RX1 (0.69) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL22498804 | 0.99 | P2RX1 (0.68) | P2RX1P2RX3P2RX2P2RY1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144972-B2 | Composition for hot-start reverse transcription reaction or hot-start reverse transcription polymerase chain reaction | BIONEER CORPORATION (KR) | 2018-12-04 | — | — | US | claimed |
| EP-2824189-B1 | COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION | BIONEER CORP (KR) | 2018-01-31 | — | — | EP | claimed |
| EP-2837696-B1 | HIGH-SENSITIVITY NUCLEIC ACID PREPARATION METHODS FOR THE DETECTION OF NUCLEIC ACID BY NUCLEIC ACID POLYMERASE | BIONEER CORP (KR) | 2018-01-31 | — | — | EP | claimed |
| US-20150072351-A1 | HIGH-SENSITIVITY NUCLEIC ACID PREPARATION METHODS FOR THE DETECTION OF NUCLEIC ACID BY NUCLEIC ACID POLYMERASE | BIONEER CORPORATION (KR) | 2015-03-12 | — | — | US | claimed |
| EP-2837696-A2 | METHOD FOR PREPARING A NUCLEIC ACID WITH HIGH PRECISION USED IN DETECTING A NUCLEIC ACID WITH A NUCLEIC ACID POLYMERASE | Bioneer Corporation (KR) | 2015-02-18 | — | — | EP | claimed |
| US-20150044683-A1 | COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION | BIONEER CORPORATION (KR) | 2015-02-12 | — | — | US | claimed |
| EP-2824189-A1 | COMPOSITION FOR HOT-START REVERSE TRANSCRIPTION REACTION OR HOT-START REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION | Bioneer Corporation (KR) | 2015-01-14 | — | — | EP | claimed |
| US-4708935-A | (2-5')-Oligo (3'-deoxyadenylate) and derivatives thereof | RESEARCH CORPORATION (US) | 1987-11-24 | — | — | US | claimed |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2022-09-29 | — | — | US | disclosed |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2022-06-07 | — | — | US | disclosed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-3683225-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | Nucana PLC (GB) | 2020-07-22 | — | — | EP | disclosed |
| WO-1991018115-A1 | PROMOTER LIGATION ACTIVATED TRANSCRIPTION AMPLIFICATION OF NUCLEIC ACID SEQUENCES | LIFE TECHNOLOGIES, INC. (US) | 1991-11-28 | — | — | WO | disclosed |
| EP-0420872-A1 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. | UNIV TEMPLE (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4859768-A | Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4708935-A | (2-5')-Oligo (3'-deoxyadenylate) and derivatives thereof | RESEARCH CORPORATION (US) | 1987-11-24 | — | — | US | disclosed |
| US-4539313-A | VIRICIDES | RESEARCH CORPORATION (US) | 1985-09-03 | — | — | US | disclosed |
| US-4464359-A | VIRICIDES | RESEARCH CORPORATION (US) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306675-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | P2RX1 1355/4885P2RX3 1110/4885P2RX2 1248/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | P2RX1 1384/4885P2RX3 1153/4885P2RX2 1293/4885 |
| US-11352387-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, RNMT, ADA | P2RX1 2019/4885P2RX3 1614/4885P2RX2 1840/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | P2RX1 216/4885P2RX3 296/4885P2RX2 261/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | P2RX1 1355/4885P2RX3 1110/4885P2RX2 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.